The 75% CIDP responder rate and streamlined trial design significantly de-risk the CAPTIVATE program and support accelerated path to Part B top-line data by YE'26. With ~$1.2B cash runway into 2030 and multiple catalysts across gMG, CIDP, MMN, and DNTH212 over the next 6-18 months, the risk/reward is skewed positively. Monitor Ph. 3 gMG EMERGE initiation in mid-2026 and Ph. 2 MMN data in Q4'26 as the next key value inflection points.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $82.07entry
- T+1 · 5mo ago +0.54%α −1.23% · $82.51
- T+5 · 5mo ago +0.51%α −0.16% · $82.49
- T+20 · 4mo ago +18.92%α +17.14% · $97.60
- T+60 · 2mo ago +32.97%α +29.71% · $109.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dianthus Therapeutics posted an updated corporate presentation disclosing a 75% confirmed responder rate from the first 40 patients completing Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP. The data supports an early GO decision and a streamlined trial design with ~1/3 fewer Part B patients, with Part B top-line guidance expected by YE'26. The filing also reiterates upcoming catalysts: Ph. 3 gMG EMERGE initiation (mid-'26), Ph. 2 MMN MoMeNtum data (Q4'26), and Ph. 1 DNTH212 data (2H'26).
Key Facts
- 75% confirmed responder rate (30 of 40) in Part A of CAPTIVATE Ph. 3 CIDP trial, exceeding the 50% threshold for GO decision
- CAPTIVATE trial design streamlined: Part B reduced from 192 to 128 patients, Part A enrollment capped at 256 vs. 480
- No related serious infections, no clinical symptoms of DIL, no related SAEs or discontinuations in interim analysis
- Cash position of ~$1.2B as of March 31, 2026, with runway into 2030
- FDA Orphan Drug Designation received May 2026 for claseprubart in Myasthenia Gravis
- Ph. 3 gMG EMERGE trial initiation expected mid-2026 with top-line data 2H'28
- Ph. 2 MMN MoMeNtum top-line data expected Q4'26
- Ph. 1 DNTH212 healthy volunteer top-line data expected 2H'26
Financial Impact
No financial figures reported in filing; cash position of ~$1.2B disclosed as of March 31, 2026
Risk Factors
- Interim analysis based on only 40 patients, final Part A and Part B results may differ
- Ph. 3 gMG EMERGE top-line data not expected until 2H'28, a long wait for pivotal readout
- Competitive landscape includes approved C5 inhibitors (Soliris, Ultomiris), FcRn blockers (Vyvgart), and emerging aC1s competitors (riliprubart, empasiprubart)
- ANA positivity observed in 36.4% of 600mg/4mL arm in Ph. 2 gMG, though no clinical DIL symptoms reported
- All pipeline candidates are investigational, no approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001690585-26-000029 |
| Document: dnth-20260612.htm | 0001690585-26-000029 |
| Document: 0001690585-26-000029-index-headers.html | 0001690585-26-000029 |
| Document: 0001690585-26-000029-index.html | 0001690585-26-000029 |
| Document: 0001690585-26-000029.txt | 0001690585-26-000029 |
Track record
23 reports on DNTH
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers